Sign In
Buy BGNE
$184.71
+0 (+0%)
At Close: Mar 28, 2025
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
President Trump demands drugmakers slash prices within 60 days
06:54am, Friday, 01'st Aug 2025
CNBC's Joe Kernen reports on the latest news.
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
06:00am, Tuesday, 27'th May 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
06:00am, Thursday, 22'nd May 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference
06:01am, Tuesday, 13'th May 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announc
Undercovered Dozen: Richtech Robotics, Intesa Sanpaolo, BeiGene, Analog Devices +
01:05pm, Monday, 12'th May 2025
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks weekly, providing investment ideas and sparking community discussion on their potential. Graham Corporation and Legal & General Grou
BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit
09:24am, Thursday, 08'th May 2025
BeiGene, Ltd., soon to be BeOne Medicines, is a global oncology company with a strong focus on innovative cancer treatments, particularly Brukinsa and Tevimbra. Brukinsa, a BTK inhibitor, has shown im
BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript
02:04pm, Wednesday, 07'th May 2025
BeiGene, Ltd.
Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat
11:01am, Wednesday, 07'th May 2025
BeiGene Ltd. ONC stock is trading lower after the company reported mixed first-quarter 2025 financial results on Wednesday.
Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics
10:35am, Wednesday, 07'th May 2025
The headline numbers for BeiGene (ONC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
06:00am, Wednesday, 07'th May 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines, Ltd., today announ
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
03:32pm, Tuesday, 29'th Apr 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today
BeiGene to Announce First Quarter 2025 Financial Results on May 7
06:01am, Thursday, 17'th Apr 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will re
BeiGene initiated with an Outperform at RBC Capital
06:15am, Monday, 07'th Apr 2025
RBC Capital initiated coverage of BeiGene with an Outperform rating and $312 price target. RBC sees a path to robust revenue growth driven by Brukinsa's market dominance and high-value follow-on asset
